Vol. 3, No. 6 — June 2026Independent since 2024

TheCompound Journal

Reporting on incretins, compounding & the peptide supply chain

A monthly journal of record.
30 issues · 32 contributors
Not medical advice. We sell nothing.

Testing Dispatch

Janoshik result on a Nantong mazdutide lot lands 0.9 points below the supplier’s figure

The result is unremarkable. What the report omits is not.

Janoshik has released a batch of 15 analytical reports on research-grade mazdutide lots, including material from GGPeps and JEEP. Reported purities range across roughly 0.9 percentage points, and the report set is unusual in stating the analytical method for every determination rather than for some of them.

Content by elemental nitrogen determination returned 87% of the labelled nominal mass, which on a 10 mg vial corresponds to roughly 14.92 mg of peptide rather than the labelled figure. The remainder is accounted for by counter-ion, residual water and residual solvent, none of which is visible chromatographically.

Purity became this trade’s single figure of merit because it is the cheapest measurement to obtain and the easiest to compare. Peptide content, which determines how much drug is actually in a vial, costs several times as much and is not offered as a standard release test by any of the twenty companies in the Journal’s dossier programme. Sterility and endotoxin are separate disciplines again, and are neither tested nor claimed.

Alastair Renshaw, pharmaceutical supply-chain consultant, was more cautious. "One lot tells you about one lot. I would not draw a conclusion about a company from a single determination, and I would not let a company draw one either."

GGPeps’s dossier has been updated with this determination and with the date of the request for comment. The dossier’s "what we could not verify" box records the questions still outstanding.

Related coverage